Financial Performance - Total operating revenue for Q1 2023 was ¥377,745,248.80, a decrease of 4.4% compared to ¥394,174,107.03 in Q1 2022[22]. - Total operating costs for Q1 2023 were ¥323,064,529.03, down 3.5% from ¥335,382,040.09 in Q1 2022[22]. - Net profit for Q1 2023 was ¥35,256,628.40, a slight decrease of 2.7% from ¥36,246,721.16 in Q1 2022[23]. - The net profit attributable to shareholders for Q1 2023 was CNY 37,373,824.55, an increase of 4.33% year-over-year[30]. - The total comprehensive income for Q1 2023 was ¥23,039,552.43, compared to a loss of ¥42,196,397.05 in Q1 2022[23]. - Basic earnings per share remained stable at ¥0.08 for both Q1 2023 and Q1 2022[23]. - The company reported a basic earnings per share of CNY 0.08 for Q1 2023, unchanged from the previous year[30]. Assets and Liabilities - The total assets as of Q1 2023 were 5,247,791,551.14 RMB, a decrease from 5,284,619,414.55 RMB in the previous period[19]. - The total non-current assets were 2,950,834,014.00 RMB, down from 2,974,590,727.49 RMB[19]. - The total current liabilities decreased to 1,412,669,461.64 RMB from 1,471,494,581.46 RMB[19]. - The total liabilities amounted to ¥1,571,850,968.19, a decrease from ¥1,630,964,993.11 in the previous period[20]. - The equity attributable to shareholders of the parent company was ¥3,577,205,736.94, an increase from ¥3,555,802,379.28[20]. - The equity attributable to shareholders increased to CNY 3,577,205,736.94, reflecting a growth of 0.60% year-over-year[31]. Cash Flow - The net cash flow from operating activities for Q1 2023 was CNY 27,030,268.28, down by 10.09% compared to Q1 2022[30]. - Cash received from operating activities totaled CNY 402,970,860.77 in Q1 2023, slightly up from CNY 402,509,153.30 in Q1 2022[25]. - Cash paid for goods and services in Q1 2023 was CNY 102,356,677.01, down from CNY 106,814,353.67 in the same period last year[25]. - Investment activities generated a net cash flow of -$22.64 million, compared to -$24.44 million in the previous period, indicating an improvement of approximately 7.3%[46]. - Cash outflow from investment activities totaled $32.65 million, up from $24.52 million year-over-year, representing a 33.1% increase[46]. - Cash flow from financing activities resulted in a net outflow of -$9.74 million, compared to -$8.74 million in the previous period, reflecting an 11.4% increase in outflow[46]. - The ending balance of cash and cash equivalents was $1.37 billion, slightly down from $1.19 billion in the previous year[46]. Research and Development - R&D expenses increased to ¥33,453,290.77 in Q1 2023, up 15.5% from ¥29,027,540.94 in Q1 2022[22]. - Clinical trial applications for the VUM02 injection have been accepted, with approvals for two indications received in February and April 2023[15]. Other Income and Expenses - Government subsidies recognized in the current period amounted to 1,075,325.83 RMB[5]. - The impairment provision reversal for receivables and contract assets was 139,815.00 RMB[5]. - Other operating income and expenses, excluding the above items, totaled 257,734.20 RMB[5]. - The total non-recurring profit and loss items amounted to 941,882.66 RMB after tax and minority interest adjustments[5]. - The company reported a decrease in other comprehensive income after tax of ¥12,217,075.97 compared to a loss of ¥78,443,118.21 in the previous year[23].

Financial Performance - The company's operating revenue for Q3 2022 was ¥407,415,406.55, representing a year-on-year increase of 4.01%[6] - The net profit attributable to shareholders for Q3 2022 was ¥49,718,296.95, a decrease of 37.94% compared to the same period last year[6] - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 111.58% year-on-year, indicating strong growth in reagent business revenue[13] - The basic earnings per share for Q3 2022 was ¥0.10, down 41.18% from the previous year[9] - Net profit for the third quarter of 2022 was ¥113,460,668.07, down from ¥194,586,517.04 in the same quarter of 2021, reflecting a decrease of approximately 41.7%[33] - The company reported a total comprehensive income of ¥81,470,494.05 for the third quarter of 2022, compared to ¥186,621,508.15 in the same quarter of 2021, a decrease of about 56.4%[35] - The company experienced a decrease in investment income, reporting ¥2,188,625.17 in 2022 compared to ¥20,486,959.81 in 2021, a decline of about 89.3%[30] Assets and Liabilities - The total assets at the end of the reporting period were ¥5,226,937,505.02, an increase of 3.85% compared to the end of the previous year[9] - As of September 30, 2022, the company's total assets amounted to RMB 5,226,937,505.02, an increase from RMB 5,033,377,672.10 as of December 31, 2021, representing a growth of approximately 3.84%[22] - The total liabilities of the company were RMB 1,596,406,723.50, compared to RMB 1,500,617,384.63 at the end of 2021, reflecting a rise of approximately 6.38%[28] - The total owner's equity was RMB 3,630,530,781.52, reflecting a stable position compared to the previous year[28] - The company’s total liabilities and equity increased to ¥5,226,937,505.02 in 2022 from ¥5,033,377,672.10 in 2021, reflecting a growth of approximately 3.8%[30] Cash Flow - The net cash flow from operating activities for the year-to-date was ¥178,308,231.45, reflecting a decrease of 23.34%[9] - The net cash flow from operating activities was 178,308,231.45, a decrease of 23.3% compared to 232,588,634.00 from the previous period[40] - Total cash inflow from financing activities was 17,500,000.00, significantly higher than 692,100.00 in the previous period[42] - The net cash flow from investing activities was -71,251,901.56, an improvement from -92,456,340.77 in the previous period[40] - Cash and cash equivalents at the end of the period reached 1,317,810,007.20, up from 1,176,968,867.46 in the previous period[42] - The total cash outflow from financing activities was 39,740,742.26, compared to 22,629,667.81 in the previous period, indicating increased financial obligations[42] - The cash inflow from operating activities totaled 1,235,684,087.35, slightly down from 1,245,397,088.82 in the previous period[40] - The cash outflow for purchasing goods and services was 299,916,803.09, an increase from 283,025,699.27 in the previous period[40] - The company received tax refunds amounting to 4,749,499.19, compared to 1,193,803.99 in the previous period, showing improved tax recovery[40] - The cash inflow from investment activities was 3,025,864.67, a significant decrease from 71,836,563.12 in the previous period[40] - The net increase in cash and cash equivalents for the period was 127,737,045.60, compared to 116,649,488.84 in the previous period[42] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 38,183[14] - The largest shareholder, Tianjin Deyuan Health Management Co., Ltd., held 12.14% of the shares, with a significant portion pledged[16] Research and Development - Research and development expenses for the first three quarters of 2022 were ¥109,497,085.50, up from ¥102,165,541.66 in 2021, marking an increase of about 7.3%[30]

Financial Performance - The company's operating revenue for the first half of 2022 was approximately RMB 768.80 million, a slight increase of 0.09% compared to RMB 768.10 million in the same period last year[21]. - The net profit attributable to shareholders of the listed company decreased by 41.44% to RMB 64.83 million from RMB 110.70 million year-on-year[21]. - The net profit after deducting non-recurring gains and losses was RMB 54.22 million, down 25.17% from RMB 72.45 million in the previous year[21]. - The net cash flow from operating activities was RMB 105.78 million, a decrease of 13.60% compared to RMB 122.43 million in the same period last year[21]. - Basic earnings per share decreased by 41.67% to RMB 0.14 from RMB 0.24 in the same period last year[22]. - The weighted average return on net assets was 1.87%, down 1.29 percentage points from 3.16% in the previous year[25]. - The company achieved operating revenue of 769 million RMB, a year-on-year increase of 0.09%[26]. - The decline in net profit was primarily due to the previous year's full exemption of the "U.S. PPP loan" and a decrease in the fair value changes of investments in associated companies[26]. - The company reported a gross margin of 74.82% in the service sector, which decreased by 2.62% compared to the previous year[53]. - In the manufacturing sector, the gross margin was 65.92%, reflecting a decrease of 0.95% year-on-year[53]. Assets and Liabilities - The total assets at the end of the reporting period were RMB 5.11 billion, an increase of 1.53% from RMB 5.03 billion at the end of the previous year[21]. - The net assets attributable to shareholders of the listed company increased by 0.41% to RMB 3.48 billion from RMB 3.46 billion at the end of the previous year[21]. - Total assets increased to CNY 5,110,355,629.70, up from CNY 5,033,377,672.10, representing a growth of 1.53%[178]. - Current liabilities rose to CNY 1,415,375,843.32, compared to CNY 1,395,646,643.11, reflecting an increase of 1.27%[178]. - Total liabilities amounted to CNY 1,547,942,962.15, up from CNY 1,500,617,384.63, indicating a growth of 3.15%[178]. - Shareholders' equity increased to CNY 3,562,412,667.55 from CNY 3,532,760,287.47, marking a rise of 0.84%[178]. Research and Development - The company is actively advancing clinical projects and cell drug development to improve its research and development capabilities[30]. - R&D expenses decreased by 7.69% to 64.51 million RMB compared to the previous year[62]. - The company has established a GMP-grade iPSC library to accelerate the process of allogeneic cell therapy[49]. - The company plans to focus on market expansion and new product development as part of its future strategy[184]. - The company is focused on developing new products in the in vitro diagnostic sector to maintain market competitiveness[88]. Market and Industry Trends - The company operates in the "precision medicine" sector, focusing on cell detection, in vitro diagnostics, and stem cell applications[30]. - The domestic in vitro diagnostic market is expected to maintain rapid growth due to factors such as economic development, healthcare reform, aging population, and increased disposable income, with significant market potential ahead[91]. - The government is prioritizing the development of immune cell therapy and gene therapy, indicating a strong future market for these technologies[33]. - The emphasis on early disease prevention and health services aligns with the growing consumer demand for healthcare solutions[33]. Corporate Governance and Compliance - The company has established independent financial and operational structures to maintain the integrity of its assets and financial decisions[114]. - The company has committed to not engaging in competitive business activities with the listed company and will ensure compliance with relevant regulations regarding related party transactions[111]. - The company guarantees the independence of its financial personnel, ensuring they do not hold positions or receive compensation from related enterprises[126]. - The company has established a robust organizational structure to ensure independent governance and decision-making processes[120]. Legal and Regulatory Matters - The company has ongoing significant litigation regarding a land use rights transfer dispute, with a judgment requiring a repayment of 71.21 million yuan from Singapore Huide Investment Holdings Co., Ltd.[145]. - The company is involved in a lawsuit concerning a 67% equity transfer dispute, with a settlement requiring a payment of 30 million yuan, of which only 1 million yuan has been received to date, leaving a balance of 29 million yuan outstanding[145]. - There are no significant guarantees or violations reported during the reporting period[142]. - The company has not faced any standard audit opinion issues in the previous annual report[145]. Social Responsibility - The company has been recognized for its social responsibility efforts, including the establishment of the "Zhongyuan Harmony Life Science Award" to support young scientists[44].

证券代码：600645 证券简称：中源协和 公告编号：2022-047 中源协和细胞基因工程股份有限公司 关于参加 2022 年度天津辖区上市公司半年报业绩说 明会与投资者网上集体接待日活动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●召开时间：2022年9月6日（星期二）13:40-16:40 ●召开地点：全景路演（http://rs.p5w.net） ●召开方式：网络方式召开 一、会议情况 为进一步加强与投资者的沟通交流，公司定于2022年9月6日（星期二） 13:40-16:40在全景路演参加2022年度天津辖区上市公司半年报业绩说明会与投 资者网上集体接待日活动。本次活动将采用网络远程的方式举行，投资者可登录 全景路演（http://rs.p5w.net）参与本次互动交流，与公司互动交流时间为 15:00-16:30。 二、召开时间和方式 时间：2022年9月6日（星期二）13:40-16:40 地点：全景路演（http://rs.p5w.net） 方式：网络方式召开 三、公司出席人员 公司出 ...

Financial Performance - The company's operating revenue for Q1 2022 was RMB 394,174,107.03, representing a year-on-year increase of 7.50%[6] - The net profit attributable to shareholders of the listed company was RMB 35,823,760.85, showing a decrease of 21.36% compared to the same period last year[6] - The basic and diluted earnings per share were both RMB 0.08, reflecting a decline of 20.00% year-on-year[6] - Net profit for Q1 2022 was approximately RMB 36.25 million, a decrease of 20.9% from RMB 45.81 million in Q1 2021[34] - The total equity attributable to shareholders decreased to approximately RMB 3.42 billion in Q1 2022 from RMB 3.46 billion in Q1 2021, a decline of 1.2%[32] - The total comprehensive income attributable to the parent company was -42,619,357.36 CNY, compared to 198,663,061.28 CNY in the previous year, indicating a significant decline[37] Cash Flow and Liquidity - The net cash flow from operating activities decreased by 38.83% to RMB 30,064,712.75, primarily due to increased procurement costs and higher performance bonuses paid to employees[11] - The net cash flow from operating activities was 30,064,712.75 CNY, down from 49,151,166.35 CNY year-over-year, reflecting a decrease of approximately 38.9%[41] - Cash received from the sale of goods and services was 395,390,920.90 CNY, an increase of 4.1% from 380,293,037.07 CNY in the previous year[41] - The total cash outflow from operating activities was 372,444,440.55 CNY, compared to 337,776,132.89 CNY in the previous year, reflecting an increase of approximately 10.2%[41] - The cash outflow from financing activities was 8,739,581.93 CNY, compared to 2,489,757.56 CNY in the previous year, indicating a significant increase in cash outflow[43] - The net cash flow from investment activities was -24,442,765.20 CNY, an improvement from -69,072,037.84 CNY in the previous year, showing a reduction in cash outflow from investments[41] Assets and Liabilities - Total assets at the end of the reporting period were RMB 5,042,570,476.68, a slight increase of 0.18% from the end of the previous year[9] - The company's total liabilities increased to approximately RMB 1.55 billion in Q1 2022 from RMB 1.50 billion in Q1 2021, reflecting a growth of 3.7%[30] - As of March 31, 2022, the total current assets amounted to RMB 2,083,470,848.81, an increase from RMB 2,030,210,899.72 at the end of 2021[27] - The company's non-current assets totaled RMB 2,959,099,627.87, down from RMB 3,003,166,772.38 at the end of 2021[27] - The company's accounts receivable increased to RMB 498,494,250.32 from RMB 456,387,269.65 at the end of 2021, reflecting a growth of approximately 9.1%[27] - The company reported a decrease in cash and cash equivalents to RMB 1,190,853,808.99 from RMB 1,195,655,271.02 at the end of 2021[27] Shareholder Information - The total number of common shareholders at the end of the reporting period was 38,735[14] - The largest shareholder, Tianjin Development Zone Deyuan Investment Development Co., Ltd., held 12.14% of the shares, amounting to 56,787,503 shares[14] Investments and Agreements - The company invested RMB 20 million in Shanghai Zhongyuan Jisheng Cell Technology Co., holding a 50% equity stake after the capital increase[19] - The company signed a real estate lease agreement with Shanghai Yanlan Biotechnology Co., with an annual rent of RMB 7,256,784 for a 5,232 square meter property[22] - The total rental payment after discounts is RMB 60,956,985.60, with the first payment of RMB 17,960,540.40 due initially[22] Research and Development - Research and development expenses for Q1 2022 were approximately RMB 29.03 million, slightly down from RMB 29.77 million in Q1 2021[32] Other Financial Metrics - Non-recurring gains and losses totaled RMB 379,000.08 for the period, with government subsidies contributing RMB 273,114.23[10] - The weighted average return on net assets was 1.04%, a decrease of 0.26 percentage points compared to the previous year[6] - The company's deferred income tax liabilities were approximately RMB 34.12 million in Q1 2022, slightly down from RMB 34.70 million in Q1 2021[30] - The total comprehensive income for Q1 2022 included a significant other comprehensive loss of approximately RMB 78.44 million, contrasting with a gain of RMB 153.11 million in Q1 2021[34] - The company's cash and cash equivalents were not explicitly stated but are implied to be part of the overall financial health reflected in the total assets of approximately RMB 5.04 billion[32] - The company reported a credit impairment loss of approximately RMB 5.32 million in Q1 2022, compared to RMB 6.07 million in Q1 2021, indicating an improvement[34]

Financial Performance - The company's audited net profit for 2021 was CNY 85.0134 million, with a cumulative undistributed profit of -CNY 156 million as of December 31, 2021, resulting in no profit distribution to shareholders[7]. - Total operating revenue for 2021 reached CNY 1.535 billion, representing a 16.41% increase compared to CNY 1.319 billion in 2020[25]. - The net profit attributable to shareholders of the listed company was CNY 155.32 million, a significant recovery from a loss of CNY 126.86 million in 2020[25]. - The net cash flow from operating activities for 2021 was CNY 320.96 million, reflecting a 31.35% increase from CNY 244.35 million in 2020[25]. - The net profit after deducting non-recurring gains and losses was CNY 55.05 million, compared to a loss of CNY 211.75 million in the previous year[25]. - The company did not implement capital reserve transfers to increase share capital or other forms of distribution due to negative retained earnings[7]. - The net profit attributable to shareholders of the listed company turned from a loss to a profit, mainly due to an increase in revenue and a reduction in goodwill impairment loss of 265 million yuan from the previous year[27]. - Basic earnings per share improved to 0.33 yuan, compared to a loss of 0.27 yuan in the previous year[27]. - The weighted average return on net assets increased by 8.28 percentage points to 4.52%[27]. - The company achieved operating revenue of CNY 1.535 billion, an increase of 16.41% compared to the previous year[77]. - The net profit attributable to shareholders was CNY 155.32 million, with a net profit of CNY 55.05 million after deducting non-recurring gains and losses, marking a turnaround from losses in the previous year[77]. Research and Development - Research and development investment accounted for 9.55% of revenue, significantly higher than the industry average in 2020[37]. - The company invested CNY 146.70 million in R&D in 2021, representing 9.55% of total revenue, which is above the industry average[45]. - The number of R&D personnel increased to 206 in 2021, accounting for 9.23% of the total workforce[45]. - The company completed 54 out of 116 R&D projects during the reporting period, including 48 projects related to stem cell research and product development[45]. - The company has established a comprehensive research and development system, collaborating with renowned hospitals and experts to advance stem cell clinical projects and drug development[69]. - The company aims to enhance R&D capabilities and improve operational efficiency across its precision medical industry chain[65]. - The company is committed to advancing research in stem cell technology, as indicated by its involvement in national key research projects[58]. - The company has developed a leading antibody research and production platform, offering a wide range of protein products and solutions in the research field[69]. Market Expansion and Strategy - The company aims to strengthen its position in the cell and gene therapy sector, which is seen as a key growth area in the biopharmaceutical industry[37]. - The company is actively collaborating with agents, insurance, and banking clients to enhance its market presence and professional image in adult cell storage[59]. - The company is focused on expanding its market presence in both domestic and international pathology diagnosis markets[63]. - The company is exploring innovative cooperation models with top-tier hospitals to enhance industrial development[76]. - The company is expanding its market presence in Asia, targeting a 10% market share by the end of the next fiscal year[163]. - The company plans to enhance its immune cell storage business as a new growth point, focusing on product design, agency policies, and optimizing online business systems, particularly in mature markets like Shanghai, Zhejiang, Hubei, and Henan[134]. Clinical and Product Development - The company is advancing clinical approval for two targeted drug screening kits for lung and colorectal cancer, with nearly 50% of sample enrollment completed[42]. - The company is conducting a clinical trial for mesenchymal stem cells, with 31 out of 36 participants enrolled for the treatment of chronic periodontitis[48]. - The CNCT19 cell injection, developed by a subsidiary, has entered Phase II clinical trials for acute lymphoblastic leukemia and non-Hodgkin lymphoma, and received orphan drug designation from the FDA[48]. - The company has successfully obtained clinical research approval for umbilical cord mesenchymal stem cells to treat refractory diabetic peripheral neuropathy[48]. - The company has completed the filing of multiple clinical research projects in collaboration with various hospitals, enhancing its research capabilities[76]. Financial Management and Governance - The total remuneration paid to all directors, supervisors, and senior management during the reporting period amounted to CNY 12.7026 million[177]. - The company implemented a director and supervisor allowance system, with the remuneration plan for senior management approved by the board's remuneration and assessment committee[177]. - The company faced regulatory penalties, including a warning letter issued by the China Securities Regulatory Commission to the former actual controller for non-operating fund occupation[178]. - The company has maintained compliance with its articles of association regarding profit distribution policies[197]. - The independent directors have provided their opinions on the profit distribution plan, confirming its legality and compliance[197]. Operational Efficiency - The company has optimized its quality management system to enhance product quality and operational efficiency, including improvements in NK cell preparation processes[49]. - The establishment of a financial shared service center is underway to enhance operational efficiency and risk management[50]. - The online platform for the life bank has been upgraded, resulting in improved operational efficiency and customer binding rates[50]. - The company is focused on operational efficiency improvements to strengthen its industry position as it expands its adult cell storage business from broad coverage to targeted key regions[59]. Industry Trends and Challenges - The biopharmaceutical industry is witnessing a shift towards more standardized practices and increased emphasis on endogenous innovation, with significant advancements in new technologies and drug approvals[123]. - The domestic clinical research landscape for stem cell therapy is robust, with 111 projects registered, covering various medical categories[126]. - The in vitro diagnostic market in China is expected to grow rapidly due to economic development, healthcare reform, and increasing disposable income, with significant competition emerging[144]. - The company faces risks related to industry policies, particularly in advanced technologies like stem cells and gene testing, which may be subject to future regulatory changes[140].

Financial Performance - The company's operating revenue for Q3 2021 was ¥391,700,257.34, representing an increase of 11.95% compared to the same period last year[7]. - The net profit attributable to shareholders for Q3 2021 was ¥80,118,557.13, reflecting a significant increase of 54.74% year-over-year[7]. - The basic earnings per share for Q3 2021 was ¥0.17, up by 54.55% year-over-year[10]. - Net profit for the third quarter of 2021 was ¥194,586,517.04, compared to ¥133,093,977.65 in the previous year, indicating a growth of 46.1%[33]. - The company reported a profit before tax of ¥259,681,320.22, up from ¥170,448,436.72, representing a growth of 52.2%[33]. - Total comprehensive income for the period was CNY 186,621,508.15, a decrease from CNY 283,669,410.36 in the previous period[35]. - Basic and diluted earnings per share increased to CNY 0.41 from CNY 0.28 year-over-year[35]. Assets and Liabilities - The total assets at the end of the reporting period were ¥5,180,605,540.72, an increase of 6.17% from the end of the previous year[10]. - The total assets of the company were reported at ¥5,180,605,540.72, an increase from ¥4,879,569,536.17 year-over-year[24]. - Current liabilities totaled ¥1,382,441,046.85, compared to ¥1,300,015,430.19 in the previous year, showing an increase of approximately 6.3%[24]. - The company's total liabilities increased to ¥1,493,581,632.30 from ¥1,377,191,804.90, showing a rise of 8.4%[26]. - The total equity attributable to shareholders of the parent company rose to ¥3,586,855,067.12, up from ¥3,396,348,979.10, marking an increase of 5.6%[26]. Cash Flow - The net cash flow from operating activities for the year-to-date was ¥232,588,634.00, reflecting a year-over-year increase of 53.40%[10]. - Cash inflow from operating activities totaled CNY 1,245,397,088.82, up from CNY 1,060,592,301.77 in the previous year[39]. - Net cash flow from operating activities was CNY 232,588,634.00, compared to CNY 151,618,311.80 in the same period last year[39]. - Cash outflow from investment activities was CNY 164,292,903.89, significantly lower than CNY 735,223,631.40 in the previous year[39]. - Net cash flow from investment activities was negative CNY 92,456,340.77, compared to a positive CNY 306,040,337.65 in the previous year[39]. - Total cash inflow from financing activities was CNY 692,100.00, down from CNY 35,876,865.61 in the previous year[39]. - Net cash flow from financing activities was negative CNY 21,937,567.81, compared to negative CNY 72,575,923.72 in the previous year[39]. Shareholder Information - The company reported a total of 38,203 common shareholders at the end of the reporting period[14]. - The major shareholder, Tianjin Development Zone Deyuan Investment Development Co., Ltd., held 12.14% of the shares[14]. Investments and Expenses - Research and development expenses for the third quarter were ¥102,165,541.66, compared to ¥93,035,969.44 in the same quarter of 2020, reflecting a 9.1% increase[29]. - The company attributed the increase in net profit to the fair value gains from the fund shares held by its foreign subsidiary Aceso[13]. - Total operating costs amounted to ¥1,000,760,328.15, up from ¥857,674,929.78, reflecting a significant increase in expenses[29]. Other Financial Metrics - The weighted average return on equity for Q3 2021 was 2.22%, an increase of 0.79 percentage points compared to the same period last year[10]. - The deferred income tax liabilities increased significantly to ¥35,481,489.27 from ¥14,405,856.03, indicating a rise of 146.5%[26]. - The company recorded a decrease in other comprehensive income after tax, amounting to -¥7,965,008.89, compared to an increase of ¥150,575,432.71 in the previous year[33]. - The company reported a decrease in inventory, which stood at ¥217,958,041.29, down from ¥222,395,516.19[21]. - The company's goodwill remained stable at ¥722,634,814.15, unchanged from the previous year[24].

Financial Performance - The company achieved operating revenue of RMB 768.10 million in the first half of 2021, representing a growth of 23.99% compared to the same period last year [20]. - The net profit attributable to shareholders of the listed company was RMB 110.70 million, an increase of 36.12% year-on-year [20]. - The net profit attributable to shareholders after deducting non-recurring gains and losses reached RMB 72.45 million, showing a significant growth of 207.12% compared to the previous year [20]. - The net cash flow from operating activities was RMB 122.43 million, up 44.75% from the same period last year [20]. - Basic earnings per share for the reporting period were RMB 0.24, up 41.18% from RMB 0.17 in the same period last year [21]. - The weighted average return on net assets increased to 3.16%, up by 0.79 percentage points compared to the previous year [21]. - The company reported a non-recurring profit of approximately RMB 38.25 million, with government subsidies contributing RMB 17.70 million and other non-operating income totaling RMB 2.17 million [25]. - The company achieved a revenue of 768.1 million RMB, representing a year-on-year growth of 23.99% [52]. - The net profit attributable to shareholders reached 110.7 million RMB, an increase of 36.12% compared to the previous year [52]. - The net profit after deducting non-recurring gains and losses was 72.5 million RMB, showing a significant growth of 207.12% year-on-year [52]. Business Operations - The company focuses on "precision medicine" with a business model that includes direct sales and a nationwide marketing network, enhancing R&D capabilities and product offerings [27]. - The precision prevention business includes newborn stem cell storage and adult cell storage, with significant roles in treating blood system diseases and immune regulation [31]. - The precision diagnosis segment offers a range of products and services, including in vitro diagnostic reagents and genetic testing, covering various diseases such as tumors and cardiovascular conditions [32]. - The precision treatment business encompasses stem cell and immune cell therapies, with ongoing clinical project registrations and drug development efforts [33]. - The company operates the Tianjin umbilical cord blood stem cell bank, which has provided 2,760 units of cord blood for disease treatment as of June 2021 [40]. - The company has established a self-cell resource bank covering two-thirds of the country, storing various types of stem cells [40]. - The company’s CAR-T cell therapy product CNCT19 has entered clinical phase II for acute lymphoblastic leukemia and non-Hodgkin lymphoma [43]. - The company’s subsidiary has developed a tumor-targeted drug gene testing kit, which is currently in clinical trial stages [43]. - The company’s subsidiary, Zhongyuan Weikang, has exclusive cooperation with AGNEA for lung cancer and colorectal cancer targeted drug gene testing in China [43]. Market and Regulatory Environment - Recent policies, including the "three-child policy," are expected to positively impact the newborn storage business by potentially increasing birth rates [37]. - The revised Medical Device Supervision and Administration Regulations are set to enhance innovation and quality in the medical device industry, benefiting the in vitro diagnostic market [38]. - The government is working on regulations for biomedical new technologies, which will provide clearer guidelines for stem cell clinical research and applications, supporting industry development [39]. - The in vitro diagnostic market in China has reached a scale of over 100 billion RMB, with a growth rate exceeding 15% post-2020 pandemic [41]. - The domestic biochemical diagnostic reagent import substitution rate has surpassed 60%, with over 200 domestic manufacturers competing in the market [43]. Research and Development - The company’s R&D expenses increased by 27.86% to 69.9 million RMB compared to the previous year [58]. - The company has completed 6 clinical research project filings for stem cell therapy, including projects for hepatitis B cirrhosis and chronic kidney disease [43]. - The company plans to collaborate with Peking University Third Hospital on reproductive health and sports medicine research projects [43]. Financial Position and Assets - The total assets of the company at the end of the reporting period were RMB 5,173.29 million, an increase of 6.02% compared to the end of the previous year [20]. - The net assets attributable to shareholders of the listed company were RMB 3,625.68 million, reflecting a growth of 6.75% year-on-year [20]. - The company reported total current assets as of June 30, 2021, amounted to CNY 1,997,714,317.90, an increase from CNY 1,915,103,978.70 as of December 31, 2020, reflecting a growth of approximately 4.2% [136]. - Cash and cash equivalents were reported at CNY 1,107,763,440.48, up from CNY 1,060,319,378.62, indicating an increase of about 4.4% [136]. - The company’s long-term equity investments increased by 20.24% to CNY 248,523,728.20 [63]. - The company reported a net loss of ¥600,149,047.78, an improvement from a loss of ¥710,853,180.48 in the previous period [140]. Shareholder and Governance - The total number of common shareholders as of the end of the reporting period is 36,442 [125]. - The largest shareholder, Tianjin Development Zone, holds 12.14% of shares, with a total of 56,787,503 shares [125]. - The company has established principles for related party transactions to ensure fairness and protect the interests of minority shareholders [101]. - The company guarantees that any future business opportunities that may compete with its main business will be promptly communicated to the company, ensuring priority for the company in such cases [99]. - The company has committed to avoiding any form of direct or indirect competition with its subsidiaries, ensuring no similar business activities will be conducted in the future [106]. Legal and Compliance Issues - The company is involved in significant litigation regarding the transfer of 8,000 acres of state-owned land use rights, with a court ruling requiring repayment of CNY 71.21 million [115]. - A civil mediation agreement from December 2018 mandates a payment of CNY 30 million for a share transfer, of which only CNY 1 million has been received, leaving a balance of CNY 29 million unpaid [115]. - The company has not faced any major penalties or compliance issues during the reporting period [118]. Risks and Challenges - The company faces industry policy risks due to the advanced technology in its main business areas, including stem cells and gene testing, which may be subject to future regulations [84]. - Talent retention is a concern as the company requires skilled personnel across various fields, and there is a risk of core personnel turnover impacting development [84]. - The company operates globally with branches in the US, Germany, and China, exposing it to foreign exchange risks due to currency fluctuations affecting financial performance [84].

证券代码：600645 证券简称：中源协和 公告编号：2021-018 中源协和细胞基因工程股份有限公司 关于举行"投资者网上集体接待日"活动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ●召开时间：2021年5月19日（星期三）15:00-16:30 ●召开方式：网络方式召开 ● 投 资 者 在 接 待 日 活 动 召 开 前 登 录 全 景 网 互 动 平 台 中 源 协 和 页 面 （https://ir.p5w.net/c/600645.shtml）进行提问，或在召开当天15:00-16:30 登录"全景·路演天下"（http://rs.p5w.net）参与本次互动交流。 一、说明会类型 中源协和细胞基因工程股份有限公司（以下简称"公司"）于2021年4月24 日发布了2020年年度报告。为便于广大投资者更深入全面地了解公司情况，公司 将在全景网以网络方式举行"投资者网上集体接待日"活动。 二、召开时间和方式 时间：2021年5月19日（星期三）15:00-16:30 方式：网络方式召开 ...

Financial Performance - Net profit attributable to shareholders increased by 644.70% to CNY 45,553,625.54 year-on-year[12] - Operating revenue rose by 32.44% to CNY 366,683,497.82 compared to the same period last year[12] - Basic and diluted earnings per share both reached CNY 0.10, up 900.00% from CNY 0.01 in the previous year[12] - The significant increase in net profit was primarily due to the full waiver of the "PPP loan" approved by the SBA during the reporting period[18] - The net profit for Q1 2021 was ¥45,810,334.85, compared to a net profit of ¥5,889,050.84 in Q1 2020, representing a significant increase[45] - The comprehensive income total for Q1 2021 was ¥198,919,770.59, compared to ¥12,329,379.82 in Q1 2020, indicating strong growth[45] Cash Flow - Net cash flow from operating activities surged by 1,491.49% to CNY 49,151,166.35 year-on-year[12] - Cash flow from operating activities for Q1 2021 was ¥49,151,166.35, a significant increase from ¥3,088,365.70 in Q1 2020[55] - The net cash flow from operating activities for Q1 2021 was -8,926,947.28 RMB, an improvement from -20,879,853.57 RMB in Q1 2020[57] - Total cash inflow from operating activities was 58,829,999.63 RMB, compared to 46,385,745.41 RMB in the same period last year, representing a 26.8% increase[57] Assets and Liabilities - Total assets increased by 5.05% to CNY 5,126,007,661.74 compared to the end of the previous year[12] - Total liabilities reached ¥1,424,710,159.88, up from ¥1,377,191,804.90, marking a growth of around 3.44%[33] - Current liabilities rose to ¥1,324,843,654.87, compared to ¥1,300,015,430.19, indicating an increase of approximately 1.91%[31] - The company’s long-term borrowings decreased by 28.56% compared to the beginning of the year, due to the full exemption of previously applied loans[22] - The total assets as of Q1 2021 amounted to 4,879,569,536.17 RMB, a decrease from 4,935,894,374.98 RMB in the previous year[61] Shareholder Information - The number of shareholders at the end of the reporting period was 35,892[15] - The total equity attributable to shareholders increased to ¥3,595,012,040.38 from ¥3,396,348,979.10, reflecting a growth of about 5.85%[33] Expenses - Sales expenses increased by 47.93% year-on-year, mainly due to increased operating income during the reporting period[25] - Financial expenses decreased significantly by 1053.00% year-on-year, primarily due to increased interest income from deposits[25] - Research and development expenses for Q1 2021 were ¥29,769,464.49, slightly up from ¥27,897,123.35 in Q1 2020[44] Government Support - The company received government subsidies amounting to CNY 13,133,781.52, which are included in the current profit and loss[15] - Other income increased by 1690.68% year-on-year, mainly due to the full exemption of the "U.S. PPP Guarantee Program Loan" approved by the SBA[25] Investment Activities - Investment activities generated a net cash outflow of approximately 69.07 million, a decrease of 191.29% year-on-year, mainly due to structural deposits[28] - The company reported investment income losses of ¥2,564,779.24 in Q1 2021, compared to a gain of ¥2,314,299.99 in Q1 2020, indicating a downturn in investment performance[50] Changes in Financial Position - Other receivables increased by 142.83% to CNY 68,566,787.22 compared to the beginning of the year[19] - Other receivables rose significantly to ¥173,528,094.16 from ¥131,063,690.60, indicating an increase of approximately 32.5%[37] - Cash and cash equivalents decreased to ¥449,653,162.93 from ¥486,133,836.39, a decline of approximately 7.51%[33]